| scholarly article | Q13442814 |
| P356 | DOI | 10.4155/PPA.12.60 |
| P698 | PubMed publication ID | 24236924 |
| P2093 | author name string | Jeffrey A Pfefferkorn | |
| Angel Guzman-Perez | |||
| Kevin J Filipski | |||
| Meihua Tu | |||
| P2860 | cites work | Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited | Q27783587 |
| Mining chemical information from open patents | Q28743320 | ||
| Chemography: the art of navigating in chemical space. | Q30986108 | ||
| Patent data mining: a tool for accelerating HIV vaccine innovation | Q33874576 | ||
| Assessing the potential of glucokinase activators in diabetes therapy | Q34976240 | ||
| Knowledge discovery in biology and biotechnology texts: a review of techniques, evaluation strategies, and applications | Q36184644 | ||
| Mining chemical structural information from the drug literature | Q36396530 | ||
| Glucokinase activators for diabetes therapy: May 2010 status report | Q36783849 | ||
| Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature | Q37810292 | ||
| Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis | Q37859008 | ||
| Competitive intelligence and patent analysis in drug discovery | Q38225075 | ||
| Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study | Q42925831 | ||
| Allosteric activators of glucokinase: potential role in diabetes therapy | Q44517691 | ||
| Exploiting structural information in patent specifications for key compound prediction | Q45224632 | ||
| SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1. | Q46512394 | ||
| Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. | Q51363512 | ||
| Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients. | Q54496427 | ||
| Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. | Q54557986 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 545-554 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Pharmaceutical patent analyst | Q26867046 |
| P1476 | title | Building structure-activity insights through patent mining. | |
| P478 | volume | 1 |
Search more.